Stockreport

Exelixis unveils additional data on Cabometyx for neuroendocrine tumors [Seeking Alpha]

Exelixis, Inc.  (EXEL) 
Last exelixis, inc. earnings: 2/25 04:05 pm Check Earnings Report
PDF Results from the phase 3 CABINET trial, presented at the European Society for Medical Oncology Congress, showed that at a median follow-up of 13.8 months, median progre [Read more]